In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.

Researchers from Charité – Universitätsmedizin Berlin and the Max Delbrück Center have detailed the precise mechanism through which the inflammatory signaling molecule IL-12 contributes to Alzheimer's ...

Microglia, the brain's immune cells, usually serve as diligent guardians. They eliminate intruders such as microbes and clear ...

Researchers have detailed the precise mechanism through which the inflammatory signaling molecule IL-12 contributes to Alzheimer's disease.

Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 ...

A new study reveals that IL-12, an inflammatory molecule, accelerates Alzheimer’s disease by damaging brain cells and ...

HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...

The IL-23 pathway is already targeted by various injectable antibody-based drugs, including AbbVie's own Skyrizi (risankizumab) – which is FDA-approved for plaque psoriasis, psoriatic arthritis ...